Hampton J R
Queen's Medical Centre, University Hospital, Nottingham, UK.
Eur Heart J. 1996 Apr;17 Suppl B:17-20. doi: 10.1093/eurheartj/17.suppl_b.17.
There are good theoretical reasons for supposing that long-term treatment with a beta-blocker would improve symptoms and survival in patients with heart failure. A series of small studies have shown that beta-blockers improve haemodynamic parameters, but it is well known that these correlate poorly with symptoms. There is some evidence that exercise tolerance is also improved. Although there is so far no convincing evidence that beta-blockers prolong survival in patients with heart failure the development of a new generation of these drugs with additional vasodilating properties makes further large studies essential.
有充分的理论依据推测，使用β受体阻滞剂进行长期治疗可改善心力衰竭患者的症状并提高生存率。一系列小型研究表明，β受体阻滞剂可改善血流动力学参数，但众所周知，这些参数与症状的相关性较差。有证据表明运动耐量也有所提高。尽管目前尚无令人信服的证据表明β受体阻滞剂能延长心力衰竭患者的生存期，但新一代具有额外血管舒张特性的此类药物的研发使得进一步开展大型研究至关重要。
